Related references
Note: Only part of the references are listed.Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start
Bianca M. L. Stelten et al.
NEUROLOGY (2019)
Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis
P. Barton Duell et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes
Maria del Mar Amador et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2018)
Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series
Denes Zadori et al.
NEUROLOGICAL SCIENCES (2017)
Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX)
Gerald Salen et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2017)
Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment
Hidde H. Huidekoper et al.
EUROPEAN JOURNAL OF PEDIATRICS (2016)
Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis
Andrea Mignarri et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2016)
A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis
Andrea Mignarri et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2014)
Neurological Outcome in Cerebrotendinous Xanthomatosis Treated With Chenodeoxycholic Acid: Early Versus Late Diagnosis
Gilad Yahalom et al.
CLINICAL NEUROPHARMACOLOGY (2013)
Cerebrotendinous xanthomatosis
Ingemar Bjorkhem
CURRENT OPINION IN LIPIDOLOGY (2013)
ESI-MS/MS quantification of 7α-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis
Andrea E. DeBarber et al.
CLINICA CHIMICA ACTA (2010)
Cerebrotendinous xanthomatosis - Possible higher prevalence than previously recognized
MT Lorincz et al.
ARCHIVES OF NEUROLOGY (2005)
Share Paper
